| Name | Title | Contact Details |
|---|
Fluid Air is a Aurora, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
MedPharm is a world-leading contract provider of topical and transdermal product design and development services. Our delivery of robust and innovative research has commanded recognition from regulators and investors alike. We utilise our unique cost-effective performance testing models to mitigate risk and accelerate development times.
Save time, money and resources with the smarter, simpler, and safer way to handle regulated medical waste
Novartis provides healthcare solutions that improve and extend people`s lives. We use science-based innovation to address some of society`s most challenging healthcare issues. We discover and develop breakthrough treatments and find new ways to deliver them to as many people as possible. Our company is focused on industry-leading divisions with innovation power and global scale: pharmaceuticals, eye care and generic medicines Novartis is headquartered in Basel, Switzerland. Novartis Group companies employ approximately 120,000 associates and its products are available in more than 180 countries around the world.
ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics to treat severe forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS® platform, which uses a novel technology to encapsulate drug substances inside red blood cells, ERYTECH is developing a pipeline of product candidates for patients with high unmet medical needs. ERYTECH`s primary focus is on the development of product candidates that target the altered metabolism of cancer cells by depriving them of amino acids necessary for their growth and survival. The Company`s lead product candidate, eryaspase, which consists of L-asparaginase encapsulated inside donor-derived red blood cells, targets the cancer cell`s altered asparagine and glutamine metabolism. Eryaspase is in Phase 3 clinical development for the treatment of second-line pancreatic cancer and in Phase 2 for the treatment of triple-negative breast cancer. ERYTECH is based in Lyon, France and Cambridge, MA, USA, and has manufacturing sites in Lyon, France, and Princeton, New Jersey, USA.